Caerulein and cholecystokinin octapeptide (CCK-8): sedative and anticonvulsive effects in mice unaffected by the benzodiazepine antagonist Ro 15-1788.
Cholecystokinin octapeptide (CCK-8), caerulein and diazepam inhibited exploratory rearing activity and harman-induced convulsions in mice. Pretreatment with the selective benzodiazepine receptor antagonist Ro 15-1788, reduced or abolished the sedative and anticonvulsive effects of diazepam, but left the same effects of both peptides unaffected. The peptide-induced ptosis was even increased by Ro 15-1788. The results suggest that the CCK-like peptides do not directly interact with the benzodiazepine receptor.
D000818:Animals; D000927:Anticonvulsants / Q000037:antagonists & inhibitors; D001570:Benzodiazepinones / Q000494:pharmacology*; D001763:Blepharoptosis / Q000139:chemically induced; D001831:Body Temperature / Q000187:drug effects; D002108:Ceruletide / Q000037:antagonists & inhibitors*; D002766:Cholecystokinin / Q000037:antagonists & inhibitors*; D003975:Diazepam / Q000037:antagonists & inhibitors*; D005442:Flumazenil; D006247:Harmine / Q000031:analogs & derivatives; D006993:Hypnotics and Sedatives / Q000037:antagonists & inhibitors; D008297:Male; D051379:Mice; D010446:Peptide Fragments / Q000037:antagonists & inhibitors*; D012640:Seizures / Q000139:chemically induced; D012844:Sincalide
D000927:Anticonvulsants; D001570:Benzodiazepinones; D006993:Hypnotics and Sedatives; D010446:Peptide Fragments; D005442:Flumazenil; D006247:Harmine; C005010:harman; D002108:Ceruletide; D002766:Cholecystokinin; D012844:Sincalide; D003975:Diazepam